Effects of Nasal High Flow Therapy on Ventilation and Gas Exchange in Healthy Newborns

Not Applicable

Completed

• Conditions: Respiratory Support
• Interventions: Device: Nasal High Flow

• Registration Number: NCT02632825
• Lead Sponsor: Research Center of Maternal and Child Health Protection, Armenia

Brief Summary

Nasal High Flow (NHF) and CPAP are established forms of respiratory support in neonates and often produce similar clinical outcomes. It has been shown in adults that NHF produce different effects on ventilation during wakefulness and sleep. There is no physiological data on effects of NHF in neonates. The physiological effects may be impacted by sleep/awake status.

Detailed Description

The aim of the study to investigate the effects of NHF therapy on ventilation and gas exchange during wakefulness and sleep in healthy term newborns.

Interventions:

NHF will be applied at 8 L/min (AIRVO 2) via (OPT 316) Optiflow nasal cannula interface without supplemental oxygen. Participants will act as their own control (no intervention) in a randomized crossover study design.

Physiological measurements:

1. Ventilation will be assessed using Respiratory Inductance Plethysmography (RIP) (Respitrace QDC, Viasys, USA).

2. Blood carbon dioxide (CO2) and oxygen levels will be measured by a non-invasive transcutaneous monitor (Tosca, Radiometer, Demnark).

3. All experiment will be recorded using Analogue-to-Digital converter (Powerlab, ADInstruments, New Zealand) and LabChart software with video recording of the patient.

4. Sleep/awake statuss will be determined by videorecording of the patient and Electroencephalogram (EEG) (Alice Polysomnography System Philips, USA)

5. The total study time will be \<3 hours in total for each participant. Routine measurement of heart rate, respiratory rate and oxygen saturation will be performed as per standard neonatal clinical practice.

6. Intervention can be terminated if at any time SpO2 drops below 80%, TcCO2 increases above 60 mm Hg, Respiratory Rate increases above 80 breaths per min for more than one minute).

The researcher is an experienced neonatal consultant will be conducting the research and observing the baby throughout the study.

Protocol:

Both control and NHF intervention periods will last a maximum of 40 min each. The maximum duration of the study including set-up, calibration, intervention, washout ans control will be \<3 hours. At the beginning of the study when all probes are attached a self-calibration period of RIP will be followed by a calibration of breathing volume with a pneumotachometer attached to a nasal mask. After all calibrations are completed a baseline measurement will be followed by either NHF 8 L/min or a control period without NHF. At the end of this period the interventions will be changes either to control or NHF, which will follow by a washout period (no NHF) and an additional calibration of RIP with a pneumotachometer.

Study Timeline

• Study Start: 2015-05
• Study First Submitted: 2015-09-10
• Study First Submitted QC: 2015-12-16
• Study First Posted: 2015-12-17
• Primary Completion: 2016-04
• Study Completion: 2016-05
• Status Verified: 2019-10
• Last Update Submitted: 2019-10-29
• Last Update Posted: 2019-10-31

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

• Healthy full or near full-term newborns of 1-2 days of age.
• A parent has given written informed consent to their baby's participation.

Exclusion Criteria

• Infants who are clinically unstable and unsuitable for non-invasive respiratory support as judged by consultant clinician or required supplemental oxygen.
• Known upper airway, lower respiratory tract, cardiac or gastrointestinal tract anomaly.
• A parent has not given written informed consent.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Nasal High Flow	Nasal High Flow	NHF will be applied at 8 L/min (AIRVO 2) through (OPT 316) Optiflow nasal cannula interface without supplemental oxygen

Primary Outcome Measures

Name	Time	Method
Change of minute ventilation	Up to 1 hour	Change of minute ventilation measured with calibrated Respiratory Inductance Plethysmography
Change of respiratory rate	Up to 1 hour	Change of respiratory rate measured with Respiratory Inductance Plethysmography

Secondary Outcome Measures

Name	Time	Method
Tissue oxygen	Up to 1 hour	Change of transcutaneous oxygen
Tissue carbon dioxide	Up to 1 hour	Change of transcutaneous tissue carbon dioxide
Heart rate	Up to 1 hour	Heart rate measured with pulseoximeter
Oxygen saturation	Up to 1 hour	SpO2

Trial Locations

Locations (1)

Neonatal Intensive Care Unit, Research Centre of Maternal and Child Health; 🇦🇲 Yerevan, Armenia